| |
| |
|
| Insider
Information: |
Mahony Susan |
| Relationship: |
Director |
| City: |
Indianapolis |
| State: |
IN |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
40,685 |
|
|
Indirect Shares
|
18,339 |
|
|
| Direct
Value |
$31,779,054 |
|
|
|
Indirect Value
|
$14,324,593 |
|
|
| Total
Shares |
59,024 |
|
|
| Total
Value |
$46,103,646 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Eli Lilly & Co |
LLY |
SVP & Pres., Lilly Onc... |
2018-04-16 |
40,685 |
2018-04-16 |
18,339 |
Premium* |
|
|
Horizon Pharma, Inc. |
HZNP |
Director |
2023-10-06 |
0 |
2023-10-06 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| HZNP |
Horizon Pharma, Inc. |
Director |
– • – |
2023-10-06 |
4 |
D |
$116.50 |
$1,084,149 |
I/I |
(9,306) |
0 |
0 |
- |
|
| HZNP |
Horizon Pharma, Inc. |
Director |
– • – |
2023-10-06 |
4 |
D |
$116.50 |
$1,088,693 |
D/D |
(9,345) |
0 |
0 |
- |
|
| HZNP |
Horizon Pharma, Inc. |
Director |
– • – |
2023-04-28 |
4 |
D |
$111.16 |
$208,870 |
D/D |
(1,879) |
2,034 |
0 |
- |
|
| HZNP |
Horizon Pharma, Inc. |
Director |
– • – |
2023-04-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,913 |
3,913 |
0 |
- |
|
| HZNP |
Horizon Pharma, Inc. |
Director |
– • – |
2022-04-29 |
4 |
D |
$98.56 |
$163,412 |
I/I |
(1,658) |
16,617 |
0 |
- |
|
| HZNP |
Horizon Pharma, Inc. |
Director |
– • – |
2022-04-29 |
4 |
OE |
$0.00 |
$0 |
I/I |
4,223 |
18,275 |
0 |
- |
|
| HZNP |
Horizon Pharma, Inc. |
Director |
– • – |
2021-04-30 |
4 |
D |
$94.62 |
$412,259 |
I/I |
(4,357) |
14,052 |
0 |
- |
|
| HZNP |
Horizon Pharma, Inc. |
Director |
– • – |
2021-04-30 |
4 |
OE |
$0.00 |
$0 |
I/I |
11,098 |
18,409 |
0 |
- |
|
| HZNP |
Horizon Pharma, Inc. |
Director |
– • – |
2020-05-02 |
4 |
OE |
$0.00 |
$0 |
I/I |
12,036 |
12,036 |
0 |
- |
|
| HZNP |
Horizon Pharma, Inc. |
Director |
– • – |
2020-05-02 |
4 |
D |
$35.62 |
$168,305 |
I/I |
(4,725) |
7,311 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
SVP & Pres., Lilly Oncology |
• – – |
2018-04-16 |
4/A |
S |
$80.08 |
$1,391,710 |
D/D |
(17,379) |
40,685 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
SVP & Pres., Lilly Oncology |
• – – |
2018-04-16 |
4 |
AS |
$80.08 |
$1,391,710 |
D/D |
(17,379) |
28,273 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
SVP & Pres., Lilly Oncology |
• – – |
2018-04-13 |
4 |
AS |
$80.14 |
$413,923 |
D/D |
(5,165) |
45,652 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
SVP & Pres., Lilly Oncology |
• – – |
2018-02-01 |
4 |
D |
$81.45 |
$776,463 |
D/D |
(9,533) |
50,817 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
SVP & Pres., Lilly Oncology |
• – – |
2018-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,326 |
60,350 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
SVP & Pres., Lilly Oncology |
• – – |
2018-01-29 |
4 |
A |
$87.60 |
$1,087,291 |
D/D |
12,412 |
51,436 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
SVP & Pres., Lilly Oncology |
• – – |
2018-01-29 |
4 |
A |
$87.60 |
$119,399 |
I/I |
1,363 |
14,872 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
SVP & Pres., Lilly Oncology |
• – – |
2018-01-29 |
4/A |
A |
$87.60 |
$119,574 |
I/I |
1,365 |
14,874 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
SVP & Pres., Lilly Oncology |
• – – |
2017-12-04 |
4 |
AS |
$86.18 |
$3,152,895 |
D/D |
(36,585) |
54,885 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
SVP & Pres., Lilly Oncology |
• – – |
2017-11-03 |
4 |
GD |
$0.00 |
$0 |
D/D |
15,861 |
39,024 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
SVP & Pres., Lilly Oncology |
• – – |
2017-02-01 |
4 |
D |
$77.03 |
$352,027 |
D/D |
(4,570) |
91,470 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
SVP & Pres., Lilly Oncology |
• – – |
2017-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,732 |
96,040 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
SVP & Pres., Lilly Oncology |
• – – |
2017-01-27 |
4 |
A |
$75.38 |
$1,450,537 |
D/D |
19,243 |
86,308 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
SVP & Pres., Lilly Oncology |
• – – |
2017-01-27 |
4 |
A |
$75.38 |
$153,021 |
I/I |
2,030 |
13,509 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
SVP & Pres., Lilly Oncology |
• – – |
2016-12-16 |
4 |
S |
$72.68 |
$83,509 |
I/I |
(1,149) |
11,479 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
